Intern, FFBA Analytical Development
- Employer
- Legend Biotech
- Location
- Somerset, New Jersey
- Posted date
- Oct 21, 2026
View more categories
- Discipline
- Information Technology, Business/Data Analytics
- Required Education
- Bachelors Degree
- Position Type
- Full time
By clicking apply, your email address will be shared with the employer.
Job Details
Legend Biotech is a global biotechnology company dedicated to treating and, one day, curing life-threatening diseases. Headquartered in Bridgewater, New Jersey, we are advancing the next generation of cell therapy through a portfolio of innovative technologies, including autologous, allogeneic, and in vivo cell therapy approaches. Our research spans chimeric antigen receptor T-cell (CAR-T), T-cell receptor (TCR-T), natural killer (NK) cell-based therapies, and other emerging platforms designed to transform the treatment of serious diseases. From our global network of research and development sites, we are committed to discovering and developing safe, effective, and cutting-edge therapies for patients worldwide.
Legend Biotech entered into a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize CARVYKTI® (ciltacabtagene autoleucel; cilta-cel). Through this strategic partnership, we combine complementary expertise and capabilities to advance innovative immunotherapies for patients living with multiple myeloma.
Legend Biotech is seeking an Intern, FFBA Analytical Development as part of the Technical Development team based in Somerset, NJ.
Role Overview
We are seeking an enthusiastic and driven Intern to join Functional, Flow Cytometry and BioAnalytics team within our empowered Analytical Development organization. The intern will focus on supporting the development of novel flow cytometry-based methods to assess cellular metabolism in immune and engineered cell products. The project will focus on establishing robust essays to characterize metabolic states of t cells transduced with LB2501 LVV. Working closely with principal scientists in Analytical Development, the candidate will design experiments, optimize staining panels, analyze multiparametric flow cytometry data, and documentation.
Key Responsibilities
Collaborate with scientists to identify pain points in the electronic sample ascension process.
Develop and draft procedures to streamline and organize sample data and test reporting.
Observe and assist with routine testing of non-critical samples.
Perform routine laboratory activities, like equipment calibration, cleaning, and general laboratory upkeep.
Assist in the creation of accurate Electronic Laboratory Notebook entries and LIMS sample templates.
This is a closely mentored role, and most decisions about planning and execution will require collaboration,consensus and alignment with senior scientists.
Requirements
Undergraduate or master’s student in:
Immunology
Cell Biology
Molecular Biology
Biomedical Engineering
Biochemistry
Biotechnology
Preferred experience with:
Mammalian cell culture
Flow cytometry
Fluorescence-based assays
Data analysis software
Basic statistics
Strong analytical thinking
Attention to detail
Scientific curiosity
Effective communication
Microsoft Office Suite
GraphPad Prism, other data analysis tools (PowerBI, JMP, R)
Strong written and verbal English skills are required.
#Li-JR1
#Li-Hybrid
Please note: These benefits are offered exclusively to permanent full-time employees. Contractors are not eligible for benefits through Legend Biotech.
Work Authorization & Employment Eligibility
Applicants must be authorized to work in the United States. As part of our commitment to maintaining a lawful workforce and ensuring compliance with federal employment regulations, we participate in the E-Verify program. If you are selected for employment, you will be required to complete the Form I-9 process, and your employment eligibility will be verified through E-Verify in accordance with applicable federal law. We are committed to providing a fair, transparent, and welcoming hiring experience for all candidates.
EEO Statement
It is the policy of Legend Biotech to provide equal employment opportunities without regard to actual or perceived race, color, creed, religion, national origin, ancestry, citizenship status, age, sex or gender (including pregnancy, childbirth, related medical conditions and lactation), gender identity or gender expression (including transgender status), sexual orientation, marital status, military service and veteran status, disability, genetic information, or any other protected characteristic under applicable federal, state or local laws or ordinances.
Employment is at-will and may be terminated at any time with or without cause or notice by the employee or the company.
For information related to our privacy notice, please review: Legend Biotech Privacy Notice.
Company
Legend Biotech was founded as an early-stage cell therapy company in 2014. The company was the brainchild of visionary scientists who recognized that antibody-based therapeutics could potentially treat disease and possessed the backgrounds in immunology and gene editing to take the leap.
For two years, Legend Biotech, then known as the “Legend Project,” operated in a room the size of a freight elevator, with the goal of creating a cell therapy for multiple myeloma, a hematological cancer that often relapses and can become refractory. The team produced nanobodies for single-domain antibody drugs and ultimately extended the half-life of the nanobodies with proprietary technologies.
In 2015, Legend’s scientists focused on research for chimeric antigen-receptor T-cells (CAR-T) targeting the BCMA protein, making the biotech one of the first companies in the world to engineer CAR-T cells for the BCMA protein. In 2016, investigator-initiated trials began in China.
In 2017, data from the trials were presented at the American Society for Clinical Oncology (ASCO), which led to a partnership with biopharmaceutical company Janssen Biotech, Inc. to co-develop the anti-BCMA CAR-T, ciltacabtagene autoleucel (cilta-cel). Applications seeking approval of cilta-cel for the treatment of patients with RRMM are currently under regulatory review by several health authorities around the world. CARVYKTI™ (ciltacabtagene autoleucel) was approved by the U.S. Food and Drug Administration in February 2022 and received conditional marketing approval from the European Medicines Agency in May 2022.
Today Legend Biotech is a global, commercial-stage company driven by a passion for patients. We continue to build our pipeline of cell therapy platforms, which includes CAR-T, CAR-NK, CAR-γδ T and non-gene-editing CAR technologies.
Our goal is to bring hope and opportunity to patients and their families by continuing to explore unique technologies.